| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | N-terminal Arginine, N-terminal Arginylation, N-terminal Arginylated, N terminal Arginine, N terminal Arginylation, N terminal Arginylated, Amino-terminal Arginine, Amino-terminal Arginylation, Amino-terminal Arginylated, Amino terminal Arginine, Amino terminal Arginylation, Amino terminal Arginylated |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Synthetic N-terminal arginylated peptide conjugated to KLH |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
N-terminal arginylation is a post-translational modification catalyzed by arginyltransferase ATE1, in which an arginine residue is added to the N-terminus of proteins. This process plays a critical role in protein quality control, cellular stress responses, and neurodevelopment. In the nervous system, N-terminal arginylation regulates the degradation of misfolded or damaged proteins via the N-degron pathway, thereby maintaining proteostasis—a function essential for neuronal survival.
Recent studies have linked impaired arginylation to neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where accumulation of misfolded proteins and disrupted stress responses are key pathological features. Arginylation also modulates cytoskeletal dynamics and synaptic plasticity, suggesting broader roles in neuronal connectivity and cognitive function. Dysregulation of ATE1 activity has been associated with increased vulnerability to oxidative stress and endoplasmic reticulum stress, both of which are implicated in neurodegeneration.
Given its multifaceted role in neuronal health, N-terminal arginylation represents a promising target for therapeutic intervention and biomarker development in neurodegenerative disease research.
A 1:1000 dilution of SMC-263 was sufficient for detection of N-terminal Arginylation in 0.5 ug of N-terminal Arginine peptide conjugated to BSA by ECL immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-263D — Size: 100 ug: N-terminal Arginylation Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D, RRID: AB_2699880)
- SMC-263D-A390 — Size: 100 ug: N-terminal Arginylation Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-A390, RRID: AB_2699881)
- SMC-263D-A488 — Size: 100 ug: N-terminal Arginylation Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-A488, RRID: AB_2699882)
- SMC-263D-A594 — Size: 100 ug: N-terminal Arginylation Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-A594, RRID: AB_2699884)
- SMC-263D-APC — Size: 100 ug: N-terminal Arginylation Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-APC, RRID: AB_2699890)
- SMC-263D-BI — Size: 100 ug: N-terminal Arginylation Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-BI, RRID: AB_2699891)
- SMC-263D-FITC — Size: 100 ug: N-terminal Arginylation Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-FITC, RRID: AB_2699892)
- SMC-263D-HRP — Size: 100 ug: N-terminal Arginylation Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-HRP, RRID: AB_2699893)
- SMC-263D-PCP — Size: 100 ug: N-terminal Arginylation Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-PCP, RRID: AB_2699895)
- SMC-263D-RPE — Size: 100 ug: N-terminal Arginylation Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263D-RPE, RRID: AB_2699896)
- SMC-263S — Size: 12 ug: N-terminal Arginylation Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-263S, RRID: AB_2699880)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Deka K., et al. (2016) Cell Death Discov. 2: 16074.